KOSDAQBiotech & Pharma156100

L&K Biomed

₩4,270▼ 1.73%2026-11-18 close
Market Cap
₩95.4B
Turnover
₩500M
Volume
120K
Shares out.
22.4M
PER
—
PBR
1.6×
EPS
-₩576
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas Sales Growth Meets a Profit Conversion Test

Revenue grew for three consecutive years through 2025 and rose in each of the last three quarters, but the net loss attributable to controlling shareholders totaled KRW 11.3 billion over the last four quarters, so converting operating gains into net profit is the central challenge.

  1. 1

    Revenue expanded from KRW 19.8 billion in 2022 to KRW 38.9 billion in 2025, and Q3 2026 revenue of KRW 12.2 billion rose 21.2% year on year.

  2. 2

    Operating profit turned positive in Q1 2026 and reached KRW 1.27 billion in Q2 and KRW 868 million in Q3, although the 2025 operating margin of 1.8% was well below 8.5% in 2024.

  3. 3

    The net loss attributable to controlling shareholders swung back to KRW 11.4 billion in Q3 2026, and press reports cited currency and composite financial instrument valuation effects as major drivers.

  4. 4

    Cumulative PECTUS sales rose 63% year on year, and partnerships with Medtronic and Precision Spine along with expanded plant capacity are cited as growth drivers.

  5. 5

    Operating cash flow was negative in every year from 2022 to 2025, reaching negative KRW 13.9 billion in 2025.

02

Business structure

L&K Biomed is a spine implant manufacturer that is classified under the bio and pharmaceutical sector on KOSDAQ.

Its core line is the thoracolumbar product family, and press reports attributed the 2025 revenue increase to higher sales of its expandable cage in Southeast Asia, including Vietnam and Thailand, and in the United States.

New products include the BluEX-C expandable cervical cage and the PECTUS chest wall correction implant. PECTUS is used to correct pectus excavatum, and cumulative sales through the first three quarters of 2026 reached KRW 57 million rise?

Reports put cumulative PECTUS sales at KRW 5.7 billion, up 63% from KRW 3.5 billion a year earlier. BluEX-C is moving through hospital registration and product adoption in the United States, and the company said it has clinical references across level 1 to level 4 surgical applications.

According to a September 2026 report, the AccelFix-MIS spinal screw fixation system and the Castleloc-P cervical plate fixation system recently received US FDA clearance.

Sales run through an overseas sales network centered on the US subsidiary, and the company has recently signed agreements with Medtronic and Precision Spine.

The global spine implant market is led by large medical device companies that control distribution and clinical networks, so partner channels and product differentiation are key variables for smaller players.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.1B₩300M3.4%
2025Q4₩8.6B-₩1.2B−13.9%
2026Q1₩9.5B₩100M1.1%
2026Q2₩11.7B₩1.3B10.9%
2026Q3₩12.2B₩900M7.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩19.8B-₩13.1B-₩13.6B−66.1%−111.1%389.4%
2023₩29.9B₩2B-₩1.9B6.8%−5.3%105.2%
2024₩36.1B₩3.1B₩9.7B8.5%22.9%130.5%
2025₩38.9B₩700M-₩16.3B1.8%−35.8%116.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported basis, annual revenue rose from KRW 19.8 billion in 2022 to KRW 29.9 billion in 2023 (up 51.3% year on year), KRW 36.1 billion in 2024 (up 20.7%) and KRW 38.9 billion in 2025 (up 7.8%).

Revenue has grown for three consecutive years, starting from 2022, and 2025 is the largest year in the 2022 to 2025 span. Operating profit, by contrast, fell 76.8% in 2025 to KRW 715 million, lowering the operating margin to 1.8%.

After a swing to operating profit of KRW 2.03 billion in 2023 and KRW 3.08 billion in 2024, 2025 gave back much of that gain. Management said staffing for supply-chain expansion and higher R&D spending raised costs.

The 2025 net loss attributable to controlling shareholders of KRW 16.3 billion, and a total net loss of KRW 16.8 billion, were linked in press reports to fair-value losses on composite financial instruments tied to the share price and to currency swings, after a KRW 9.74 billion profit in 2024.

Operating cash flow was negative in each year, moving from negative KRW 6.88 billion in 2022 to negative KRW 13.9 billion in 2025. The debt ratio fell from 389.4% in 2022 to 116.1% in 2025.

Total equity at the end of 2025 was KRW 38.6 billion, and equity attributable to controlling shareholders was KRW 45.5 billion, so the original filing's non-controlling interest line should be checked because total equity is smaller than the controlling portion.

Quarterly revenue bottomed at KRW 8.61 billion in Q4 2025 and then rose to KRW 9.5 billion, KRW 11.7 billion and KRW 12.2 billion across the first three quarters of 2026. Operating profit was KRW 106 million in Q1 2026, KRW 1.27 billion in Q2 and KRW 868 million in Q3, which was down 31.9% from the prior quarter.

The Q3 2026 net loss attributable to controlling shareholders of KRW 11.4 billion was reported to reflect higher overseas sales costs and a currency-translation loss from a lower exchange rate at quarter end.

05

Industry analysis

L&K Biomed's growth is concentrated in the United States and Southeast Asia. The company is widening its hospital network mainly through its US subsidiary, increasing the number of hospitals using PECTUS and BluEX-C.

In Southeast Asia, sales of the expandable cage in Vietnam and Thailand were reported to support 2025 revenue. A growing set of US FDA-cleared products can help build product credibility in talks with large device makers.

The spine implant market is controlled by large medical device companies that hold distribution networks and clinical data, so smaller players must secure partner channels and differentiate their products.

The company's plan to cut fixed selling and administrative costs and expand high-margin product supply targets profitability once the overseas sales infrastructure spending eases. On the demand cycle, spine surgery volumes and the pace at which US hospitals adopt new products are the key variables.

The company sits in the bio and pharmaceutical sector, but its business is medical devices, so metrics such as hospital adoption, surgery volume and sales channels matter more than pipeline-based pharma benchmarks.

06

Outlook

In its Q3 2026 disclosure, the company said it would pursue cost efficiency in fixed selling and administrative expenses while expanding supply of higher-margin products.

The BluEX-C expandable cervical cage's expansion in the US market was cited as a key variable for the second half, and PECTUS is planned to extend supply to major US hospitals.

According to a July 2026 report, the company acquired a new plant site and building that roughly doubles production capacity, and it will produce strategic products for collaboration with global device makers and next-generation lines there.

The same report said talks with global partners, starting with Asia, were progressing. In the Q1 2026 results coverage, staffing for new product development and supply-chain expansion was described as having raised selling and administrative costs.

The next checkpoints are when the new plant begins operating and when partner agreements start contributing to revenue. Even when agreements are disclosed, the timing of actual sales should be checked in quarterly results.

The key questions are whether the operating margin holds in the 7% range seen in Q3 2026 and whether swings in non-operating items narrow.

The 2026 annual report is due by the end of March 2027, and it will show the full-year 2026 operating margin and the structure of net income attributable to controlling shareholders.

07

Valuation

PER
—
PBR
1.6×
ROE
-21.0%
EPS
-₩576
BPS
₩2,640
Dividend per share
₩0

Because the last four quarters carry a cumulative net loss attributable to controlling shareholders, a price-to-earnings ratio cannot be calculated on that basis. The price-to-book ratio sits above 1x, which means the market is paying a premium over net assets.

Still, total equity at the end of 2025 was smaller than the controlling shareholders' portion and the debt ratio was 116.1%, so any asset-based reading should be paired with a review of the balance sheet. Shareholder payouts are effectively negligible, so a dividend-based comparison adds little.

With earnings moving between profit and loss, the starting point is to read sales and operating profit trends separately from swings in non-operating items. The large change in earnings between the 2024 profit and the 2025 net loss makes past multiples hard to read as a guide to current levels.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Widening overseas sales base

Quarterly revenue went from KRW 9.5 billion in Q1 2026 to KRW 11.7 billion and KRW 12.2 billion, the third consecutive quarterly gain. Cumulative PECTUS sales up 63% show the chest wall product is diversifying the revenue mix. Broader hospital adoption in the US supports a wider overseas sales base.

Operating profit stays positive

Q1 2026 operating profit of KRW 106 million turned positive from a prior-quarter loss. Q2 operating profit rose to KRW 1.27 billion, and Q3 operating profit of KRW 868 million was up 156.6% year on year. Press reports put the Q3 operating margin at 7.1%, up from 3.4% a year earlier. The company said continued selling-cost efficiency could sustain this trend.

New products and global partnerships

The company recently signed agreements with Medtronic and Precision Spine and is broadening its range with the BluEX-C cervical cage and PECTUS. A July 2026 report said the new plant acquisition roughly doubles production capacity. US FDA-cleared fixation systems have also been added to the portfolio. How quickly these factors appear in reported results is the core of the bullish case.

09

Bear factors

Net losses persist despite operating gains

The 2025 net loss attributable to controlling shareholders was KRW 16.3 billion, and the total net loss was KRW 16.8 billion. The four quarters from Q4 2025 through Q3 2026 carry a combined controlling-shareholder net loss of KRW 11.3 billion. Q3 2026 swung back to a KRW 11.4 billion loss. A pattern in which operating profit does not carry through to net profit has repeated.

Selling costs and overseas investment burden

The company says costs for building its US subsidiary sales network, along with personnel and commissions, raised selling and administrative expenses. Q3 2026 operating profit fell 31.9% from the prior quarter. The 2025 operating margin of 1.8% was far below 8.5% in 2024. How fast the costs the company calls transitional decline is the item to track.

Cash generation and debt burden

Total liabilities at the end of 2025 were KRW 44.8 billion, and the debt ratio was 116.1%. If cash outflows continue, investment capacity will depend more on external funding. Derivative gains and losses linked to convertible bonds also swing quarterly net income, which is a further bearish factor.

10

Risk factors

Non-operating earnings volatility

Press reports linked both currency translation losses at quarter end and fair-value losses on composite financial instruments to the share price to the bottom line. The Q3 2026 net loss was also explained by a currency translation loss. Operating profit can be positive while net income is negative, which makes earnings hard to read.

Pace of partner contract delivery

How quickly agreements with Medtronic and Precision Spine turn into revenue has to be checked step by step through disclosures. If new plant operations and contract volumes are out of step, selling costs could rise before revenue does. Slower-than-expected hospital adoption in the US would delay the revenue expansion from new products.

Funding and capital structure

The debt ratio at the end of 2025 was 116.1%, and operating cash flow has been negative for four straight years. Given the convertible bond redemption and derivative gains and losses, changes in the capital structure and potential dilution remain items to watch. Concurrent plant investment and overseas network expansion would raise funding needs.

11

What to watch next

  1. By late December 2026

    US hospital adoption and second-half sales trends for BluEX-C, which show whether product expansion is translating into revenue.

  2. Timing not yet announced

    Start of operations at the new plant and disclosure of global partner agreements, which indicate whether added capacity converts into supply.

  3. By March 31, 2027

    The 2026 annual report, which will show the full-year operating margin, net income attributable to controlling shareholders, non-operating items and the non-controlling interest structure.

12

Overall view

According to its filings, L&K Bio's revenue grew from KRW 19.8 billion in 2022 to KRW 38.9 billion in 2025, and quarterly revenue has risen for three consecutive quarters in 2026.

In the third quarter of 2026, it recorded revenue of KRW 12.2 billion and operating profit of KRW 870 million, so operating-level profitability has continued.

On the other hand, net loss attributable to owners of the parent swung back to a loss of KRW 11.4 billion in the third quarter, and the cumulative net loss over the last four quarters is KRW 11.3 billion.

The company explained that the net loss stemmed from higher selling and administrative expenses to build overseas sales infrastructure and from fluctuations in foreign exchange and hybrid financial instrument gains and losses.

The bullish factors are expanding U.S. sales centered on Pactus and BlueX-C, partnerships with companies such as Medtronic, and increased production capacity through the new plant.

The bearish factors are persistently negative operating cash flow, a debt ratio of 116.1%, and large volatility in non-operating gains and losses.

Which of these two sets of factors gains more weight can be gauged by how far the operating margin and the structure of non-operating gains and losses are sorted out in the 2026 annual report.

Because earnings-based multiples cannot be calculated during a net loss period, it is appropriate to focus on the trends in revenue and operating profit. This report is provided for informational purposes only and does not include any buy or sell recommendation.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. rapportian.com
  2. getnews.co.kr
  3. pointe.co.kr
  4. thepublic.kr
  5. ftoday.co.kr
  6. globalnewsagency.kr
  7. thepublic.kr
  8. view.asiae.co.kr
  9. hankyung.com
  10. kndaily.co.kr
  11. kr.investing.com
  12. dingdingz.co.kr
  13. investing.com
  14. markets.hankyung.com
  15. littlebproject.com
  16. littlebproject.com
  17. littlebproject.com
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis